Midway through Campaign's audience with Publicis Groupe's Maurice Lévy, a heavily French-accented voice exclaims, "Now it is time for the real boss to arrive."
Valeant sells Addyi back to Sprout; some advertisers halt business with Outcome Health; Amgen cuts R&D jobs
In April, a month or so after brands were accused of funding terrorist videos on YouTube, Procter & Gamble cut down the number of sites its ads ran on by 69%.
The blogger talks the challenges of influencer marketing in healthcare, chronic disease, and big brand activations.
Experimental Gilead and GSK HIV drugs are expected to compete; GSK R&D head resigns; Valeant subsidiary scores eye-drug approval
Teva reports lower-than-expected Q3 earnings; BI and Dicerna partner in NASH drug development; AstraZeneca's experimental asthma drug fails in Phase-III
Forecasts anticipate sales of $1.3 billion in five years.
The divisional VP and head of public affairs has seen it all, including the transformation from a traditional comms organization to a more dynamic and content-led group.
During its third quarter earnings call yesterday, WPP dismissed the threat from management consultants as "overhyped". Analysts concur.
Drug industry spends nearly $50 million to fight drug-price referendum; Novartis weighs sales of generic unit; ICER to evaluate all newly approved drugs
MM&M and PRWeek have revealed the 2017 Health Influencer 50, a list honoring professionals across the health spectrum for their passion, determination, and innovative thinking that has helped guide the industry through two turbulent and exciting decades.
To remain relevant, speakers bureaus must evolve to a strategic marketing tactic with personalized messaging to the customer.
Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah
Second to market and dismissed as inferior to the competition, Sanofi's Aubagio seemed destined for lower-tier status. Here's how it overcame the initial obstacles and, five years later, become a potent market force
Novartis to acquire French biotech in bid to develop new cancer therapies; FDA hires former Mylan exec as comms adviser; health system sees drop in opioid scripts
In 2013, Medicare Part D prescribers who received a gift from a drugmaker prescribed 8% more brand-name drugs.
The HealthiHER project has commissioned a survey of women aged 30 to 60 to inform future campaigns.
Porter Novelli has been appointed to lead a new global CSR brief for pharma and consumer goods giant Johnson & Johnson, as the company faces a major reputation challenge in the US.
CVS Health reportedly in talks to acquire Aetna; Amazon acquires wholesale pharmacy licenses; Merck says June cyberattack disrupted global operations
Optum vet Miller replaces Jessica Boden.
Non-profit challenges Gilead's Sovaldi patent; The Medicines Company to cut hundreds of jobs; Amgen ends R&D for experimental CETP drug
Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?
FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer's drug; GSK Q3 sales driven by HIV, respiratory drugs
The agency network is rebranding five subsidiaries under the W2O banner.
Trade group PhRMA's CEO talks about his first year in the job amid public outrage about price gouging.
FDA approves Alexion's Soliris for another rare disease; Sun Pharma debuts companion mobile app for acne drug; Hurricane halts manufacturing in Puerto Rico
Read the October 2017 issue in its entirety, including our Career and Salary Survey.
The Paris-based pharma company debuted a brand campaign and signature last week.
Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine
The drugmaker eliminated its U.S. primary care, disease-focused endocrinology, and hospital chronic-care sales teams.
From IKEA to eye-opening health campaigns, S&S Wellness' CCO helps turn emotion into action.
The organization rolled out a video this week as part of its Live Unaddicted campaign to change the perception of addiction treatment.
Merck lays off 1,800 employees, launches new sales force; Celgene ends development of Crohn's disease drug; PBMs come under increased scrutiny
Area 23 netted three gold awards, and 2e Creative won Small Agency of the Year for the third year in a row.
Two point-of-care companies have received hundreds of millions of dollars in funding. One of them, Outcome Health, is facing allegations about padding data.
The FDA approves Kite's CAR-T therapy; Omnicom reports strong Q3 performance for healthcare agencies; Hearst to acquire Rodale, up health presence
More than half of doctors say patients make critical, racist, or sexist comments; Anthem to launch its own PBM; drugmakers face criticism for waste
An FDA advisory committee is scheduled to vote Wednesday on whether to approve Novo's semaglutide, which, if approved, could steal market share from Eli Lilly's Trulicity.
The health startup's system has a foot scanner that can take photos of a patient's feet and can look for potential foot ulcers using a machine learning image classifier.
J&J reports 15% lift in pharma sales in Q3; Apple reportedly considers buying medical clinics; survey finds need for digital investment in payer marketing
Like its consumer-products cousins, pharma marketers are exercising more discipline over online media. Will it yield similar results?
FDA briefing document affirms diabetes drug's efficacy; J&J debuts new tools to improve adherence; AZ says cancer drug data was falsified
Two key creators from Ready Set Rocket share how a thoughtful execution can destigmatize mental illness.
Outcome Health reportedly misled advertisers; FDA committee recommends gene therapy; Avanir drug is highly prescribed by docs paid by company
The association said it is preparing for new FDA approvals for therapies that treat central nervous system and muscular system diseases.
Merck scraps plans for cholesterol drug; oncologist describes how he tells people about his work; researchers question list of side effects in DTC ads
Susan G. Komen and the Breast Cancer Research Foundation are focusing on raising awareness and research money for the deadliest forms of the disease.
Pfizer considers sale of its consumer healthcare business; Express Scripts moves into patient benefit management; China to speed up drug approvals
Patients complain about positive healthcare ads; some drugmakers skirt Open Payment rules; new law requires disclosure of drug price hikes in California
The communications team, led by Jeff Winton, is again researching Astellas' reputation for an updated picture on where the campaign has gotten them so far.
AbbVie to pay $140 million to AndroGel patient; Trump likely to roll back birth-control mandate; patients more likely to respond to expensive drugs
Cigna will no longer cover OxyContin; the AMA no longer supports price-fixing to lower drug prices; Gottlieb is not in favor of 'right-to-try' laws
In the 2015-16 flu season, more than 145 million doses were distributed by manufacturers, according to the Centers for Disease Control and Prevention, but only 41% of American adults received a vaccine.
The FDA approves Mylan's Copaxone generic; 3 out of every 1,000 Americans face $50,000 in drug costs; some ACA premiums may rise by 50%
DKMS worked with Marino on PR for the campaign and with Area 23 on its Comic Con booth.
The top three most advertised brands were GlaxoSmithKline's Breo Ellipta, Eli Lilly's Trulicity, and Boehringer Ingelheim's Jardiance.
The FDA wants to improve the generic drug approval process; Allergan CEO responds to criticism of patent deal; breast cancer death rate dropped 40%
The successes of these pharma execs show that there's no one path to professional bliss.
The need to simplify access to treatment while finding new ways to keep patients engaged in their health and adherent is an undeniably growing trend.
The FDA tells 75 opioid drugmakers to fund training efforts; epilepsy drug reduces seizure frequency; FDA approves Novo's fast-acting mealtime insulin
Now that Facebook, Apple, and Google have set their sights on healthcare, agencies find themselves under pressure from yet another flank.
Salaries are up — by a lot — and marketers are enthusiastic about their career prospects.
Read the September 2017 issue in its entirety, including how marketing can save clinical trials.
Merck to stop developing hep.-C drugs; FDA approves new Lilly breast-cancer drug; California bill would outlaw co-pay cards
Universities stock vending machines with women's health products; AbbVie pays to delay Amgen's Humira biosimilar; more states likely to introduce off-label bills
A leaked email chain shows that WPP intends to withdraw from Ascential's Eurobest awards in London and is in discussions with the organizer about Cannes Lions.
Accenture or CapGemini are more likely to acquire the global agency networks than a Google or Oracle, according to a leading French bank.
The answer: it depends on what phase the trial is in.
AbbVie adds context to CEO's comments on drug pricing; Pandora makes a play for pharma ad dollars; shortages expected of drugs manufactured in Puerto Rico
Some of the world's marketers have reported specific examples of where their digital advertising appeared alongside offensive and compromising content.
Execs from JWT, J&J, and DanoneWeave react to the results of a new JWT/Geena Davis Institute study.
Patient assistance nonprofit contacted in Aegerion probe; most heavily marketed drugs in Canada offer little therapeutic value; the FDA pans Duchenne drug
Still, most experts characterize this year's newly approved women's health drugs as modest improvements rather than groundbreaking advances in medicine.
The CEO and founder of Antidote talks about what inspired him to start the company, which recently received funding from Merck.
Amgen's Prolia tops the list, according to data compiled by EvaluatePharma.
The best marketers possess a mix of scientific know-how, digital dexterity, and unflappability. To keep them, agencies need to revise their thinking and tactics.
The FDA declines to approve an opioid and a treatment for rheumatoid arthritis; KKR closes WebMD buyout; 60% of teens have received the HPV vaccine
The health insurance startup launched a campaign this week that urges people to get covered.
Express Scripts' Miller says new models needed to pay for CAR-T; FDA warns about Intercept drug deaths; CVS puts limits on opioid scripts
They are tasked with addressing an increasingly tough payer environment and ongoing criticism of the industry's drug-pricing practices.
Blood Equality for GMHC by FCB Health was another honoree for Ad of the Year.
Nestle to refocus Galderma's skin health R&D; Amazon is reportedly in talks with PBMs; most Americans do not actively read science news
Beyond providing access, co-pay cards represent a starting point to more powerful patient engagement.
A "seat at the table" isn't enough, says Oath's Allison Allen, in wide-ranging discussion at annual diversity conference.
Facebook itself has more than six million health-related groups.
Pfizer sues J&J over Remicade contracts; drugmakers trim sales forces for rare-disease drugs; Roche's oncology business under siege from biosimilars
Exact Sciences has found success by marketing Cologuard in ads airing on networks like MSNBC, CNN, and Fox News.
Only three of the seven FDA-approved biosimilars are available for sale; Teva to sell off women's health portfolio; the FDA approves GSK's COPD combo
The new brand campaign, Attacking Cancer from Every Angle, showcases all the services the organization provides.
The company also this year has purchased Vynamic and Cambridge BioMarketing.
Insurers rarely require prior authorization for opioids; court of appeals voids J&J win in Advil ads suit; new California law to address drug pricing
Too few of the billions of sites online are usable for disabled people, says AudioEye's CEO.
The rise of voice technology platforms and the connected home has turned the discussion of a brand's voice from metaphorical to physical.
The FDA approves first cancer biosimilar; it also approves Bayer's new lymphoma drug; clinical-trial participation for gynecological cancer drops
Facebook chief operating officer Sheryl Sandberg has said that in turbulent times the social network must do more than simply connect people.
One-third of clinical trials are never publicly registered; ICER revises PCSK9 cost-effectiveness analysis; flu shot linked to miscarriages
Aaron Sklar, formerly of Welltok, replaces Christine Armstrong, who moved on to a Silicon Valley health startup.
Guidemark Health's Tina Fascetti offers Medela's Katie Busse advice on being a working mother in healthcare marketing.
FDA closes pediatric study loophole; little evidence outcomes-based contracts are working; PBMs lobby against transparency efforts